CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...